DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20191230

Hydralazine versus Labetalol for acute control of blood pressure in patients with severe pre-eclampsia: a randomized controlled trial

Nayanika Gaur, Priyanka Kathuria

Abstract


Background: Authors sought to compare the effectively of intravenous hydralazine and intravenous labetalol in controlling acute rise in blood pressure in patients with severe preeclampsia.

Methods: In this double-blind randomized controlled trial, all pregnant women with sustained increase in blood pressure (BP) of 160 mmHg systolic or 110 mmHg diastolic or higher were randomized to receive intravenous (IV) hydralazine 5 mg (max. 4 doses) or IV labetalol in escalating doses of 20mg, 40mg, 80mg, 80mg to achieve target blood pressure of 150 mmHg systolic and 100 mmHg diastolic or lower. The primary objective of the study was to assess the time taken to control blood pressure. Secondary agendas were the number of repeat doses required and other side effect profile.

Results: In the study duration of September 2015 to September 2017, authors enrolled 60 participants for our trial. The median time taken to achieve the target blood pressure was 22.4 minutes in both the groups. Close to half of the participants did not require repeat doses (46.66% with labetalol and 50% with hydralazine). No serious maternal or foetal side effects were noted during the study. Statistical tests were performed using SPSS for Windows version 22.

Conclusions: As operated in the study, the efficacy of hydralazine and labetalol to control the acute rise in blood pressure is similar.


Keywords


Hydralazine, Labetalol, Severe preeclampsia

Full Text:

PDF

References


Lewis G,ed. The confidential enquiry into maternal and child health (CEMACH). Saving mother’s lives: reviewing maternal deaths to make motherhood safer- 2003- 2005. The 7th report on CEMACH, London 2007)

Lori JR, Starke AE. A critical analysis of maternal morbidity and mortality in Liberia, West Africa. Midwifery 2012;28 (1):67-72.

Moraes AP, Barreto SM, Passos VM, Golino PS, Costa JA, V Ascocelos MX. Incidence and main causes of severe maternal morbidity in Sao Luis, Maranhao, Brazil: longitudinal study. Sao Paulo Med J. 2011;129(3):146-52

Mudaliar AL, Menon MKK (1978) Hypertensive disorders of pregnancy. In: Clinical Obstetrics. (7th edn),Orient Longman, Mumbai, PP.234.

Dev PK, Sultan, Sautpur SR. Review of eclampsia cases. J Obstet Gynaecol India 1976;26-53.

Chesley LC. History. In Chesley LC (ed): Hypertensive Disorder in pregnancy. Appleton-Century-Crofts, New York, 1978:17034.

Shekhar S, Sharma C, Thakur S, Verma S. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol 2013;122(5):1057-63.

NHBPEP. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(2):S1-22.

Mabie WC, Gonzalez AR, Sibai BM, Amon ER. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987;70(3 Pt 1):328-33.